June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Luca Arecco Presented in Clinical Science Symposium at ASCO25 – New data from CARRIERS study
Jun 4, 2025, 08:14

Luca Arecco Presented in Clinical Science Symposium at ASCO25 – New data from CARRIERS study

Luca Arecco, Clinical Research Fellow at ESMO, shared a post on X:

“Presented in Clinical Science Symposium at ASCO25 new data from CARRIERS study
Among >25,000 patients with BC, germline BRCA1 and BRCA2 carriers were linked to worse OS in ER+ BC
No OS impact for ATM, CHEK2, or PALB2 (PALB2 a trend to worse OS)
In >25,000 women, PVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2 were found in 6% Impact on OS was gene- and subtype-specific. For ER+ diseases: BRCA1: HR 1.8 (p=0.02) BRCA2: HR 1.8 (p<0.001)
Significant worse OS compared to non-carriers.
On the contrary, in ER-negative diseases no significant OS differences were observed across all PVs (BRCA1, BRCA2, ATM, CHEK2, PALB2) These results reinforce how tumor biology and endocrine sensitivity may drive prognosis in ER+ diseases!
In our analysis presented at ASCO24 and published in Annals Oncology we evaluated prognosis of young patients (<40y) affected by BC and harboring BRCA1 and BRCA2 PVs We included >4,500 young BRCA carriers, and these were the main findings:
– BRCA carriers with HR+ disease had similar prognosis of carriers with HR- disease
– BRCA2 carriers had worse prognosis (particularly BCSS) in year >5 from diagnosis
– Carriers with Luminal A-like diseases had poorer DFS than all the other subtypes
Both studies question the prognostic advantage of HR-positivity in BRCA carriers
HR+ BC in BRCA carriers (especially BRCA2) behave more aggressively than in sporadic cases
Time to re-evaluate (escalate) treatments in BRCA carriers with HR+ BC?”

Clinical Science Symposium

Title: Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers

Luca Arecco Presented in Clinical Science Symposium at ASCO25 - New data from CARRIERS study

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

Highlights from ASCO 2025 Day 4